Published in NIDA Res Monogr on January 01, 1997
Potential role of CYP2D6 in the central nervous system. Xenobiotica (2013) 0.84
Advances in genetic studies of substance abuse in China. Shanghai Arch Psychiatry (2013) 0.81
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther (2008) 2.49
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Nicotine metabolism defect reduces smoking. Nature (1998) 2.17
A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther (1997) 2.06
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry (2006) 1.89
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther (2009) 1.83
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol (2000) 1.82
Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci (1984) 1.64
Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther (2010) 1.59
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control (2004) 1.47
Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther (1983) 1.47
Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther (1982) 1.46
Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther (1998) 1.44
Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J (2007) 1.35
Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh) (1985) 1.27
Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol (1986) 1.23
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther (2000) 1.22
Risk factors for tobacco dependence in adolescent smokers. Tob Control (2006) 1.20
Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci (1983) 1.19
A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus. Nature (1993) 1.19
Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators. Tob Control (2002) 1.19
Biomarkers for smoking cessation. Clin Pharmacol Ther (2013) 1.15
Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther (1980) 1.14
In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. Can J Physiol Pharmacol (1982) 1.13
Pharmacogenomics at the tipping point: challenges and opportunities. Clin Pharmacol Ther (2011) 1.06
Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther (1986) 1.06
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther (2007) 1.06
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos (2001) 1.06
Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clin Pharmacol Ther (2010) 1.05
Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol (1997) 1.05
Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl (2006) 1.04
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics (1998) 1.03
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther (2012) 1.02
Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol (1980) 1.02
Debrisoquine hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther (1981) 1.01
Few cell lines with GABAA mRNAs have functional receptors. J Neurosci (1994) 1.01
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther (2011) 1.00
5-HT and alcohol abuse. Trends Pharmacol Sci (1992) 0.99
Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther (1997) 0.99
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol (2000) 0.99
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun (2002) 0.99
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol (1986) 0.98
Intercellular calcium waves in neurons. Mol Cell Neurosci (1996) 0.97
Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J Pharmacol Exp Ther (2001) 0.97
Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci (2000) 0.96
Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther (2006) 0.96
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol (1993) 0.95
Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica (2010) 0.95
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol (2001) 0.94
A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. Can J Physiol Pharmacol (1984) 0.93
The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys (1990) 0.93
Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci (2000) 0.92
Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Mol Psychiatry (2000) 0.91
Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol (1991) 0.90
CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol (1997) 0.90
Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica (2000) 0.90
Altered gabaa receptor subunit and splice variant expression in rats treated with chronic intermittent ethanol. Alcohol Clin Exp Res (2001) 0.89
Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther (1997) 0.88
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics (2001) 0.88
Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol (1995) 0.88
Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem Pharmacol (2001) 0.87
The influence of an endogenous beta3 subunit on recombinant GABA(A) receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cells. Neuropharmacology (2000) 0.87
Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics (2001) 0.86
The human dopamine D5 receptor gene: cloning and characterization of the 5'-flanking and promoter region. Biochemistry (1995) 0.86
Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. J Clin Psychiatry (1991) 0.86
Genomic medicine, precision medicine, personalized medicine: what's in a name? Clin Pharmacol Ther (2013) 0.84
CYP2A6 genotype but not age determines cotinine half-life in infants and children. Clin Pharmacol Ther (2013) 0.84
Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys. J Pharmacol Exp Ther (2012) 0.84
Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol (1999) 0.83
Cytochrome P450 2D6 and treatment of codeine dependence. J Clin Psychopharmacol (2000) 0.82
Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics (1998) 0.82
Sparteine oxidation polymorphism: a family study. Br J Clin Pharmacol (1986) 0.82
Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug Alcohol Depend (1999) 0.82
Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol (1998) 0.82
Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. Clin Pharmacol Ther (2013) 0.81
Gender-stratified gene and gene-treatment interactions in smoking cessation. Pharmacogenomics J (2011) 0.81
Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J Clin Psychopharmacol (2000) 0.80
A conditionally immortalized glial cell line that expresses mature myelin proteins and functional GABA(A) receptors. J Neurochem (1998) 0.80
Defining the true therapeutics and clinical pharmacology curriculum in a Canadian medical school: implications for change. Clin Pharmacol Ther (1988) 0.80
Neurodegenerative diseases: a growing challenge. Clin Pharmacol Ther (2010) 0.79
Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. J Pharmacol Exp Ther (1993) 0.79
Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. J Pharmacol Exp Ther (1995) 0.79
Independent and combined effects of ethanol self-administration and nicotine treatment on hepatic CYP2E1 in African green monkeys. Drug Metab Dispos (2011) 0.78
Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine. Behav Pharmacol (1997) 0.78
CYP2D6 phenotype and genotype in a Canadian Native Indian population. Pharmacogenetics (1997) 0.78
Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type. Biochem Pharmacol (1991) 0.76
Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos (2001) 0.76
The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol (2003) 0.76
Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys. Br J Pharmacol (2014) 0.76
Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. J Hum Hypertens (2012) 0.76
A simple borohydride/GC method for measuring sparteine metabolites in man. Br J Clin Pharmacol (1986) 0.75
Brain and disease: the long path to discovery and treatment. Clin Pharmacol Ther (2009) 0.75
Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. J Chromatogr B Biomed Sci Appl (1997) 0.75
Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology (1991) 0.75
Drug metabolism and interactions in abuse liability assessment. Br J Addict (1991) 0.75
Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. Mol Psychiatry (2017) 0.75